In this article, we will look at the 11 Best High Volume Penny Stocks to Buy Now.
After a prolonged period where mega-cap stocks dominated returns, smaller and more speculative names are starting to see renewed trading activity. Increased volume often reflects growing investor attention, and historically, these shifts have coincided with periods where risk appetite begins to expand across the market.
Institutional investors have started to highlight a more constructive backdrop for smaller-cap equities. Franklin Templeton’s report entitled “What’s next for US small-caps in 2026?” notes that “both small-cap quality and value are poised for meaningful rebounds in 2026,” adding that “2026 could be the year that small-caps reassert themselves.” The firm also points out that the earnings growth of small-caps is expected to beat that of large-caps in 2026. Janus Henderson echoes this view, stating that “multiple drivers beyond interest rates support small caps heading into 2026,” while noting that “small-cap valuations remain historically cheap relative to large caps.” Institutional investors are beginning to see a scenario where underfollowed and lower-priced stocks could attract more attention as capital rotates across the market.
These perspectives point to a market environment where smaller, more actively traded stocks may begin to gain relevance, especially as investors look beyond the largest names for new opportunities. With that in mind, we take a closer look at the 11 Best High Volume Penny Stocks to Buy Now.
Our Methodology
We used screeners to identify stocks that are trading below $5 per share and have an average volume of at least 5 million. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
11. Sabre Corporation (NASDAQ:SABR)
On March 13, 2026, BofA analyst Victor Cheng lowered the price target on Sabre Corporation (NASDAQ:SABR) to $2.40 from $2.90 previously and maintained a Buy rating. BofA said that Sabre Corporation is still expected to outpace Global Distribution System industry growth in air bookings, forecasting 4.3% growth in FY26 versus about 1.4% for the industry, but cited lower growth and free cash flow in the outer years for the reduced target.
On March 5, 2026, Sabre Corporation and Constellation Software, which owns approximately 12.7% of Sabre’s outstanding shares, entered into a strategic governance agreement. As part of the agreement, Sabre will appoint Damian McKay, CEO of Vela Software Group, to its Board of Directors, and the company will terminate its shareholder rights plan announced on March 1. McKay joined Vela in 2015 through the acquisition of Datamine, where McKay had served as CEO, and has held various leadership roles across energy and software businesses prior to the current position.
Last month, Sabre reported Q4 adjusted EPS of (1c) versus the (5c) consensus estimate. Revenue totaled $667M compared with the $654.08M consensus estimate. CEO Kurt Ekert said the company ended the year with “strong momentum” and is positioned for accelerating performance, noting that Sabre generated full-year positive Pro Forma Free Cash Flow and continued advancing its AI capabilities for the travel industry despite a challenging 2025.
Sabre Corporation provides software and technology solutions for the global travel industry, including its Sabre Mosaic marketplace connecting travel suppliers and buyers.
10. Humacyte, Inc. (NASDAQ:HUMA)
On March 17, 2026, Humacyte, Inc. (NASDAQ:HUMA) submitted a Marketing Authorization Application to the Israel Ministry of Health for approval of its acellular tissue-engineered vessel, Symvess, for arterial trauma repair. The company is also pursuing a pathway to make Symvess available in Israel on a hospital-by-hospital basis ahead of potential approval. Symvess is currently approved by the FDA for extremity vascular trauma, while other uses remain investigational and not yet approved by regulatory agencies.
Last month, Humacyte, Inc. presented long-term data on Symvess at the Vascular & Endovascular Surgery Society Annual Winter Meeting 2026. In the V005 trial, the product maintained structural integrity and showed low infection rates with high levels of limb salvage over follow-up periods of up to 36 months. Among 54 patients treated in the Phase 2/3 study where standard vein grafts were not feasible, outcomes stabilized after early complications, with infection-free rates reaching 92.9% from months 3 to 36 and no infections reported after day 37. Limb salvage rates were 87.3% at 12 months and 82.5% at 24 months.
Humacyte, Inc. develops and manufactures bioengineered human tissues designed for implantation across multiple therapeutic areas.
9. Kosmos Energy Ltd. (NYSE:KOS)
On March 17, 2026, Mizuho raised the price target on Kosmos Energy Ltd. (NYSE:KOS) to $2 from $1.50 previously and maintained a Neutral rating on the shares. Mizuho has increased its 2026 oil price outlook by 14% to $73.25 as the Iran conflict entered its third week, noting it is too early to determine if the conflict will structurally raise global oil prices, but said the bias is likely higher. The firm remains positive on the oil and gas sector while also lowering its fiscal 2026 natural gas price outlook by 6% despite still viewing fundamentals as constructive.
On March 11, 2026, Kosmos Energy Ltd. increased the size of its common stock offering to $185.3M from $175M, with a price range of $1.90 to $2.20. Barclays and Stifel acted as joint book-running managers for the offering. On March 10, 2026, Kosmos Energy Ltd. announced the launch of a registered underwritten public offering of $175M of common stock, with proceeds intended to repay outstanding borrowings under its commercial debt facility and other debt obligations.
Kosmos Energy Ltd. explores, develops, and produces oil and natural gas assets in offshore regions including Ghana, Equatorial Guinea, Mauritania, Senegal, and the Gulf of America.
8. Borr Drilling Limited (NYSE:BORR)
On March 11, 2026, SEB Equities analyst Kim Andre Uggedal downgraded Borr Drilling Limited (NYSE:BORR) to Hold from Buy with a $5.45 price target, citing valuation and saying the recovery in the jack-up market is already reflected in the share price.
On March 9, 2026, Borr Drilling provided an operational update following hostilities in the Arabian Gulf, where the company has four jack-up rigs deployed across Saudi Arabia, the UAE, and Qatar. Three rigs in Qatar and the UAE were down-manned as a precaution, while the Arabia III was shut down after an incident on a customer-operated platform, with all personnel safely evacuated. CEO Bruno Morand said ensuring safety remains the company’s “highest priority,” noting that operations will stay on standby until conditions allow for a safe restart. The company added that all four rigs remain under contract and insured.
Last month, Borr Drilling reported Q4 revenue of $259.4M versus the $240.06M consensus estimate and a net loss of $1.0M, improving by $28.8M from Q3. Adjusted EBITDA was $105.2M, down $30.4M sequentially. The company said operational performance remained “solid,” supported by high utilization rates, while revenue declined due to sanctions-related contract terminations and lower day rates on transitioning rigs. Management added that demand is gradually recovering, particularly in the Middle East, with a growing pipeline of long-term tenders and expectations for improving market conditions into the second half of 2026.
Borr Drilling Limited provides offshore shallow-water drilling services to the oil and gas industry across multiple global regions.
7. Peloton Interactive, Inc. (NASDAQ:PTON)
On March 17, 2026, Peloton Interactive, Inc. (NASDAQ:PTON) announced that Sarah Robb O’Hagan will join as chief content and member development officer, reporting to Chief Executive Officer and President Peter Stern, with a start date of April 1. Peloton Interactive, Inc. said Robb O’Hagan will focus on expanding its content ecosystem and driving engagement while strengthening member loyalty globally. Robb O’Hagan most recently served as CEO of Exos.
On March 16, 2026, Peloton Interactive, Inc. introduced the Peloton Commercial Series, its first bike and treadmill products designed for high-traffic gym environments. The company said the launch marks its evolution beyond at-home fitness toward a broader wellness platform, with the Commercial Series developed through its Commercial Business Unit, integrating Precor and Peloton for Business. The new lineup combines Peloton’s digital content with Precor’s industrial-grade equipment, allowing the company to expand into gyms, hospitality, and multifamily fitness spaces while leveraging Precor’s global footprint across more than 60 countries. Peloton added that the Commercial Business Unit grew revenue by 10% year over year in fiscal Q2.
Peloton Interactive, Inc. provides connected fitness products and wellness services, including exercise equipment and digital content offerings.
6. Esperion Therapeutics, Inc. (NASDAQ:ESPR)
On March 16, 2026, Esperion highlighted the inclusion of bempedoic acid in the 2026 American College of Cardiology/American Heart Association Multisociety Guideline on the Management of Dyslipidemia. The guidelines support the use of bempedoic acid across multiple patient groups to lower LDL-C and reduce cardiovascular risk, particularly in patients who cannot tolerate statins or are unable to reach target levels. Christie Ballantyne said the update reflects the importance of “earlier, aggressive combination therapy” and recognizes statin intolerance as a key challenge, pointing to broader use of additional therapies to improve long-term outcomes.
On March 13, 2026, Citizens raised the price target on Esperion Therapeutics, Inc. (NASDAQ:ESPR) to $5 from $4 and maintained an Outperform rating. Citizens said Esperion’s Q4 results were consistent with its January preannouncement and pointed to continued execution of its Vision 2040 strategy, including the acquisition of Corstasis Therapeutics and progress in advancing ESP-2001.
Esperion Therapeutics, Inc. develops and commercializes treatments for patients with elevated low-density lipoprotein cholesterol in the United States.
5. Fractyl Health, Inc. (NASDAQ:GUTS)
On March 17, 2026, H.C. Wainwright maintained a Buy rating on Fractyl Health, Inc. (NASDAQ:GUTS) with an $8 price target, addressing a sharp selloff following the company’s January data release. The firm said the update triggered a 65% decline in the shares as investors focused on “critical friction points,” including a lack of statistical significance and weight-regain trends. H.C. Wainwright, however, said the results remain consistent with prior Revita data and advised investors to “take a breath,” pointing to a potential pivotal readout in Q4 that could position Revita as a treatment option after GLP-1 therapy discontinuation.
On February 26, 2026, Fractyl Health, Inc. announced completion of participant randomization in its REMAIN-1 pivotal cohort, a double-blind study evaluating Revita for weight maintenance following GLP-1 discontinuation. CEO Harith Rajagopalan said the milestone marks an “important” step toward generating definitive clinical evidence, noting the study was designed to demonstrate Revita’s effect. Rajagopalan added that prior data and ongoing studies have informed confidence in the program as the company prepares to report topline six-month results in early Q4 2026.
Fractyl Health, Inc. develops therapies targeting metabolic diseases, including type 2 diabetes and obesity, with its Revita system designed to address duodenal dysfunction.
4. Tenaya Therapeutics, Inc. (NASDAQ:TNYA)
On March 12, 2026, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported Q4 EPS of (12c), in line with the (12c) consensus estimate. CEO Faraz Ali said the company is entering the year with “momentum” following clinical progress in 2025, highlighting encouraging data from its lead gene therapy programs. Ali noted that Tenaya expects to provide additional updates in the first half of 2026, including longer-term data from the MyPEAK-1 trial of TN-201 and new data from the RIDGE-1 trial of TN-401, while also working toward regulatory alignment on pivotal trial plans.
On March 9, 2026, Tenaya Therapeutics, Inc. presented preclinical data for TN-301, its selective HDAC6 inhibitor, at the Muscular Dystrophy Association’s Clinical & Scientific Conference 2026. In models of Duchenne muscular dystrophy, TN-301 improved muscle performance and addressed markers of muscle injury, including reductions in creatine kinase activity. The compound also showed improvements in cardiac-related cellular function, including correcting calcium handling abnormalities and mitochondrial dysfunction in human-derived cardiomyocytes.
Tenaya Therapeutics, Inc. develops gene and small molecule therapies targeting heart disease, with programs focused on cardiomyopathies and heart failure.
3. Payoneer Global Inc. (NASDAQ:PAYO)
On March 11, 2026, Payoneer Global Inc. (NASDAQ:PAYO) announced a strategic collaboration with FundPark to expand financing access for eligible e-commerce businesses in Hong Kong. The partnership will allow FundPark to offer its AI-driven digital financing solutions to Payoneer customers to support their global expansion.
On March 6, 2026, Benchmark lowered its price target on PAYO to $7 from $10 and maintained a Buy rating. Benchmark said investor focus on declining interest income from customer funds has overshadowed improving fundamentals, noting the stock has “languish near multi-year lows” despite steady growth, strong cash flow generation, and continued expansion in the global payments ecosystem.
On February 26, 2026, Payoneer reported Q4 EPS of 5c, in line with the 5c reported last year. Revenue totaled $274.69M compared with the $282.39M consensus estimate. CEO John Caplan said the company delivered “record results” in 2025, surpassing $1B in annual revenue while generating profitability and free cash flow. Caplan added that Payoneer is shifting its strategy upmarket to serve more complex SMB and SME needs while investing in an AI-first approach to improve product delivery and customer engagement.
Payoneer Global Inc. provides financial technology solutions for cross-border payments, offering multi-currency accounts and payment infrastructure for global businesses.
2. Immunic, Inc. (NASDAQ:IMUX)
On March 10, 2026, Immunic, Inc. (NASDAQ:IMUX) announced that the European Patent Office granted a key patent covering label-relevant dosing regimens for its lead asset, vidofludimus calcium. The patent is expected to protect Europe through 2038 and may be eligible for a Supplementary Protection Certificate, which could extend exclusivity to as late as 2043.
Immunic, Inc. noted that the claims broadly cover vidofludimus and its salt, solvate, and free acid forms across all label-relevant dosing regimens, meaning protection is not limited to a single formulation and may extend to alternative forms used according to the approved label. The patent had previously been granted in the United States in 2023.
On March 2, 2026, H.C. Wainwright lowered its price target on Immunic, Inc. to $5 from $8 previously and maintained a Buy rating after updating its model.
Immunic, Inc. develops oral immunology therapies targeting chronic inflammatory and autoimmune diseases, including multiple sclerosis and ulcerative colitis.
1. Ocugen, Inc. (NASDAQ:OCGN)
On March 17, 2026, Canaccord initiated coverage of Ocugen, Inc. (NASDAQ:OCGN) with a Buy rating and a $12 price target, citing the company’s three clinical-stage programs in retinal diseases and describing early data as “interesting.” Canaccord added that the upcoming Q3 data could serve as a “de-risking event” as those programs advance.
On March 11, 2026, Oppenheimer initiated coverage of OCGN with an Outperform rating and a $10 price target, viewing the company as an emerging gene therapy player in ocular disorders. Oppenheimer pointed to OCU400, currently in Phase 3 for retinitis pigmentosa, and said a potential 2027 approval could provide entry into a “sizable and poorly-met” rare disease market. Meanwhile, Lucid Capital analyst Elemer Piros raised the price target on OCGN to $22 from $15 and maintained a Buy rating following positive preliminary Phase 2 data for OCU410 in geographic atrophy.
On March 4, 2026, OCGN reported Q4 EPS of (6c), in line with the (6c) consensus estimate. CEO Dr. Shankar Musunuri described 2025 as a “transformative year,” highlighting progress across its gene therapy programs alongside licensing and financing agreements that strengthened the company’s position. Musunuri added that Ocugen is approaching the first of three planned BLA filings as it advances its pipeline.
Ocugen, Inc. develops gene and cell therapies, biologics, and vaccines focused on improving patient outcomes.
READ NEXT: 10 Must-Buy Real Estate Stocks to Invest In and 15 Stocks That Will Make You Rich in 10 Years.
Hedge Fund Resource Center